InterveXion Therapeutics Receives Japanese Patent for IXT-m200 (Anti-Methamphetamine Antibody)
InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international intellectual property estate with the allowance of a key patent in Japan. In July...
read moreInterveXion Announces Positive Results from Pre-Specified Interim Review of Phase 2 STAMPOUT Study
IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing...
read moreAsia’s meth trade is now worth an estimated $61B … with no end to the crisis in sight – CNN
Source: Asia's meth trade is now worth an estimated $61B ... with no end to the crisis in sight - CNN
read moreBinding Methamphetamine to Release People from Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). We are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
InterveXion Therapeutics Receives Japanese Patent for IXT-m200 (Anti-Methamphetamine Antibody)
InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing immunotherapies for substance abuse disorders, today announced the expansion of its international intellectual property estate with the allowance of a key patent in Japan. In July...
read moreInterveXion Announces Positive Results from Pre-Specified Interim Review of Phase 2 STAMPOUT Study
IXT-m200 produced immediate, dose-dependent, time-dependent changes in primary endpoint parameters of methamphetamine AUC and Cmax LITTLE ROCK, AR, USA, July 29, 2019 -- InterveXion Therapeutics, a private clinical-stage biopharmaceutical company developing...
read moreAsia’s meth trade is now worth an estimated $61B … with no end to the crisis in sight – CNN
Source: Asia's meth trade is now worth an estimated $61B ... with no end to the crisis in sight - CNN
read moreDeveloping Novel Therapeutics for Addiction
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Our lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 is being studied in an upcoming Phase 2 proof-of-concept study (STAMPOUT). We are also developing a novel vaccine (IXT-v100) against methamphetamine.